within Pharmacolibrary.Drugs.ATC.L;

model L01EX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.21,
    Cl             = 5.4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,
    adminCount     = 1,
    Vd             = 0.111,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005383333333333334,
    Tlag           = 1980
  );

  annotation(Documentation(
    info ="<html><body><p>Pazopanib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-Kit. It is primarily used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. Pazopanib is approved by regulatory agencies and is currently in clinical use for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with advanced solid tumors; healthy male and female, multiple ethnicities, after oral administration of pazopanib tablets.</p><h4>References</h4><ol><li><p>Mueller-Schoell, A, et al., &amp; Kloft, C (2021). Therapeutic drug monitoring of oral targeted antineoplastic drugs. <i>European journal of clinical pharmacology</i> 77(4) 441–464. DOI:<a href=&quot;https://doi.org/10.1007/s00228-020-03014-8&quot;>10.1007/s00228-020-03014-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33165648/&quot;>https://pubmed.ncbi.nlm.nih.gov/33165648</a></p></li><li><p>Imbs, DC, et al., &amp; Chatelut, E (2014). Pharmacokinetics of pazopanib administered in combination with bevacizumab. <i>Cancer chemotherapy and pharmacology</i> 73(6) 1189–1196. DOI:<a href=&quot;https://doi.org/10.1007/s00280-014-2455-3&quot;>10.1007/s00280-014-2455-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24705975/&quot;>https://pubmed.ncbi.nlm.nih.gov/24705975</a></p></li><li><p>LaPlant, KD, &amp; Louzon, PD (2010). Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. <i>The Annals of pharmacotherapy</i> 44(6) 1054–1060. DOI:<a href=&quot;https://doi.org/10.1345/aph.1M251&quot;>10.1345/aph.1M251</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20407031/&quot;>https://pubmed.ncbi.nlm.nih.gov/20407031</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EX03;
